Outcome of Cyclophosamide, Melphalan and Etoposide as a Conditioning Regimen in Autologous Bone Marrow transplantation for Relapsed Lymphomas

Abstract

igh-dose chemotherapy (HDC) and autologous PBSC support is the gold standard for relapsing or refractory lymphoma patients (Cohen et al., 2012).

During the past years, several prognostic factors have been identified, and disease status before HDC is considered the strongest factor predicting the outcome of lymphoma patients (Morschhauser et al., 2008).

Unfortunately, ~ 40% of them are unresponsive to salvage therapy and undergo HDC+PBSC when in progression of their disease or cannot undergo transplantation at all (Gisselbrecht et al., 2010).

Treatment of these patients is difficult, as most conventional salvage regimens are ineffective and this is particularly true for those patients with unresponsive disease after first-line chemotherapy (Ardeshna et al., 2005).

The current study involved 8-year follow-up of patients with primary refractory or relapsed HL who underwent autologous bone marrow transplantation in Al Sheikh Zayed specialized Hospital using cyclophosamide, melphalan and etoposide as conditioning regimen.